Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatins Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED)...
United States Carl Spana Palatin Technologies Inc Cosette Pharmaceuticals Prnewswire Palatin Technologies Inc Vyleesi To Cosette Pharmaceuticals
Source: prnewswire.com